This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Dyax Corp.
Dyax Corp., a prominent biopharmaceutical company headquartered in the United States, has been at the forefront of developing innovative therapies since its founding in 1995. Specialising in the field of rare diseases, particularly in the treatment of hereditary angioedema, Dyax has made significant strides in advancing patient care through its unique product offerings. The company is renowned for its flagship product, Kalbitor, which provides rapid relief for acute attacks of hereditary angioedema. Dyax's commitment to research and development has positioned it as a leader in the biopharmaceutical industry, with a strong focus on utilising its proprietary technology platforms to discover and develop novel therapeutics. With a robust pipeline and a dedication to improving patient outcomes, Dyax Corp. continues to solidify its reputation as a key player in the biopharmaceutical landscape.
DitchCarbon Score
How does Dyax Corp.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dyax Corp.'s score of 72 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dyax Corp., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Takeda Pharmaceutical Company Limited, which means that any climate commitments or emissions data may be inherited from its parent organisation. As part of its corporate family relationship with Takeda, Dyax Corp. aligns with the climate initiatives and targets set by Takeda. However, specific reduction targets or achievements for Dyax Corp. are not detailed in the available information. The initiatives from Takeda include commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), which are aimed at reducing greenhouse gas emissions across their operations. While Dyax Corp. does not have its own reported emissions data, it is important to note that the company is part of a broader commitment to sustainability and climate action through its association with Takeda. This includes efforts to address Scope 1, 2, and 3 emissions, although specific figures and targets for Dyax Corp. are not provided.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 96,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 161,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 226,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dyax Corp. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
